JP2013529077A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529077A5
JP2013529077A5 JP2013510352A JP2013510352A JP2013529077A5 JP 2013529077 A5 JP2013529077 A5 JP 2013529077A5 JP 2013510352 A JP2013510352 A JP 2013510352A JP 2013510352 A JP2013510352 A JP 2013510352A JP 2013529077 A5 JP2013529077 A5 JP 2013529077A5
Authority
JP
Japan
Prior art keywords
polypeptide
borrelia
nucleic acid
amino acid
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013510352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529077A (ja
JP6030052B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036525 external-priority patent/WO2011143617A1/en
Publication of JP2013529077A publication Critical patent/JP2013529077A/ja
Publication of JP2013529077A5 publication Critical patent/JP2013529077A5/ja
Application granted granted Critical
Publication of JP6030052B2 publication Critical patent/JP6030052B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013510352A 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法 Expired - Fee Related JP6030052B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
US61/334,901 2010-05-14
PCT/US2011/036525 WO2011143617A1 (en) 2010-05-14 2011-05-13 Chimeric ospa genes, proteins, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016126631A Division JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法

Publications (3)

Publication Number Publication Date
JP2013529077A JP2013529077A (ja) 2013-07-18
JP2013529077A5 true JP2013529077A5 (enExample) 2014-06-26
JP6030052B2 JP6030052B2 (ja) 2016-11-24

Family

ID=44121257

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013510352A Expired - Fee Related JP6030052B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2013510354A Expired - Fee Related JP6227407B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126631A Pending JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126608A Withdrawn JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2018129896A Withdrawn JP2018150386A (ja) 2010-05-14 2018-07-09 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2020135857A Expired - Fee Related JP6965417B2 (ja) 2010-05-14 2020-08-11 Ｏｓｐａキメラおよびそのワクチンでの使用法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2013510354A Expired - Fee Related JP6227407B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126631A Pending JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126608A Withdrawn JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2018129896A Withdrawn JP2018150386A (ja) 2010-05-14 2018-07-09 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2020135857A Expired - Fee Related JP6965417B2 (ja) 2010-05-14 2020-08-11 Ｏｓｐａキメラおよびそのワクチンでの使用法

Country Status (13)

Country Link
US (6) US8623375B2 (enExample)
EP (4) EP2569008B1 (enExample)
JP (6) JP6030052B2 (enExample)
KR (7) KR20130062954A (enExample)
CN (3) CN103108652B (enExample)
AU (2) AU2011252850B2 (enExample)
BR (2) BR112012027315B1 (enExample)
CA (2) CA2799181C (enExample)
MX (3) MX348113B (enExample)
PL (2) PL2569009T3 (enExample)
RU (2) RU2636455C2 (enExample)
SI (2) SI2569008T1 (enExample)
WO (2) WO2011143617A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623375B2 (en) 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
US20120215701A1 (en) 2010-10-20 2012-08-23 Mehta Kaushal N Flexible monetization service apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
US10096022B2 (en) * 2011-12-13 2018-10-09 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2014018274A1 (en) * 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
WO2014144521A1 (en) * 2013-03-15 2014-09-18 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
US20160213766A1 (en) * 2013-09-23 2016-07-28 Ventria Bioscience, Inc. OspA Fusion Protein for Vaccination against Lyme Disease
MX369195B (es) 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
EP3180024B1 (en) 2014-08-11 2022-05-18 University of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
WO2017029000A1 (en) * 2015-08-14 2017-02-23 Telefonaktiebolaget Lm Ericsson (Publ) A node and method for managing a packet data network connection
EP3534941A4 (en) * 2016-11-07 2020-07-08 The Wistar Institute Of Anatomy And Biology CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST LYME DISEASE
WO2018189372A1 (en) * 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
CN112584858A (zh) * 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
IL297166A (en) * 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
EP4262860A4 (en) 2020-12-17 2025-11-12 Idexx Lab Inc DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
EP4490042A4 (en) 2022-03-08 2026-03-04 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
JP2026525284A (ja) 2023-07-10 2026-07-29 ダイナヴァックス テクノロジーズ コーポレイション アジュバントおよびｂｏｒｒｅｌｉａ細胞表層タンパク質ａ抗原を含むライム病ワクチン
EP4743110A1 (en) 2023-07-10 2026-05-20 Dynavax Technologies Corporation Lyme disease vaccines containing an adjuvant and Borrelia outer surface protein A and C antigens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG122738A1 (en) * 1990-06-15 2006-06-29 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FI933580L (fi) 1991-02-15 1993-10-13 Uab Research Foundation Strukturgen av pneumokockprotein
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
WO2002016422A2 (en) * 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Recombinant constructs of borrelia burgdorferi
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
DE69433690T2 (de) 1993-11-01 2005-03-10 Brookhaven Science Associates Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
CA2244110A1 (en) 1996-02-12 1997-08-14 Cobra Therapeutics Limited Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
WO1999000413A1 (en) * 1997-06-30 1999-01-07 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
CN100351265C (zh) 2003-04-02 2007-11-28 美国政府健康及人类服务部 含胆固醇的化合物以及其用作针对伯氏疏螺旋体(Borrelia burgdorferi)的免疫原的应用
BRPI0409459A (pt) * 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
ATE466022T1 (de) * 2004-03-24 2010-05-15 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
EP1768688A4 (en) 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
AU2006320246A1 (en) 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
EP2289906A1 (en) 2006-09-15 2011-03-02 Intercell AG Borrelia antigens
ATE496935T1 (de) 2007-02-22 2011-02-15 Baxter Int Verfahren zur aufreinigung hydrophober proteine
EA200901578A1 (ru) * 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
JP5788676B2 (ja) * 2008-01-11 2015-10-07 イノビオ ファーマシューティカルズ，インコーポレイティド デングウイルスの複数のサブタイプに対する新規ワクチン
EP2274616A1 (en) 2008-04-22 2011-01-19 The Research Foundation of State University of New York Borrelia burgdorferi cell envelope protein array
WO2009135118A2 (en) 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
US8623375B2 (en) * 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
WO2014018274A1 (en) * 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2013529078A5 (enExample)
RU2012153972A (ru) Химерные гены ospa, белки и способы их применения
US20260070950A1 (en) Mutant fragments of ospa and methods and uses relating thereto
JP2011500035A5 (enExample)
JP2015522270A5 (enExample)
HRP20170094T1 (hr) Imunogeni pripravak
EP3279217A1 (en) Streptococcus pneumoniae protein antigen, and preparation method and use thereof
US20210101962A1 (en) Mosaic Chimeric Viral Vaccine Particle
WO2020074908A2 (en) Treatment and prevention of malaria
CN107033226B (zh) 一种小反刍兽疫病毒f蛋白抗原表位肽及其确定、制备方法和应用
TWI782542B (zh) 一種鞭毛蛋白的重組蛋白及其用途
CN102276725B (zh) 隐孢子虫CTL和Th混合多表位基因和融合蛋白及应用
CN103421817B (zh) 人工合成的猪繁殖与呼吸综合征病毒多表位基因及应用
CN102219858A (zh) 微小隐孢子虫ctl多表位基因和融合蛋白及其应用
KR102873285B1 (ko) 스캐폴드 기반의 다중항원을 포함하는 코로나바이러스 감염병 예방 또는 치료용 항원 조성물
CN101880328B (zh) 微小隐孢子虫Th多表位基因和融合蛋白及其应用
CN105254719B (zh) 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗
CN107034198A (zh) 一种嵌合诺如病毒p颗粒及其制备和应用
CN103243105A (zh) 一种旋毛虫重组蛋白及应用
CN110483624B (zh) 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN102847167B (zh) 一种预防奶牛乳腺炎的改进型增效核酸疫苗的构建
최훈철 Development of recombinant vaccine against Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)
CN105713096A (zh) 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
CN105384800A (zh) 金黄色葡萄球菌taf融合蛋白制备方法及其应用
CN110938150A (zh) E型肉毒毒素重组hn-l抗原的制备方法及其应用